There are currently 544 clinical trials in Madison, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Wisconsin, University of Wisconsin Hospital and Clinics, University of Wisconsin-Madison and University of Wisconsin Carbone Cancer Center - University Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786
Recruiting
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma R... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: William S. Middleton Memorial VA, Madison, Wisconsin
Conditions: Colorectal Neoplasms
Register for Updates
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654
Recruiting
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Triple Negative Breast Cancer
Register for Updates
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
NCT06568172
Recruiting
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses hig... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin +1 locations
Conditions: Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma, Resectable Head and Neck Cutaneous Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Register for Updates
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575
Recruiting
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: University of Wisconsin Carbone Cancer Center-University Hospital, Madison, Wisconsin +1 locations
Conditions: Multiple Myeloma
Register for Updates
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: University Hospital and UW Health Clinics, Madison, Wisconsin
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06203600
Recruiting
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Im... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: William S Middleton VA Medical Center, Madison, Wisconsin +2 locations
Conditions: Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Register for Updates
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559
Recruiting
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy. The primary hypotheses are that (1) nemtabrutinib is non-inferior to ibrutinib or acalabrutinib with respect to objective response rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria 2018 by blinded independent centra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University Hospital and UW Health Clinics ( Site 0006), Madison, Wisconsin
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Mindfulness and ACL Surgery
NCT05542563
Recruiting
Anterior cruciate ligament (ACL) surgery patients experience physical trauma, both in the physical injury itself and following surgery, and face potential long-lasting adverse effects such as muscle weakness, diminished joint function, hip pain, and fear. Many of these patients report more significant anxiety and depression following surgery, which can further compound these patients' adverse outcomes. This study is a single-blind, randomized controlled trial design to evaluate the effects of a... Read More
Gender:
ALL
Ages:
Between 16 years and 40 years
Trial Updated:
08/12/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: ACL, ACL Injury
Register for Updates
Evaluation of Vitamin A Absorption From Fortified Bouillon
NCT06438562
Recruiting
The goal of this clinical trial is to measure how well different formulations of vitamin A (VA) are absorbed by the body when they are added to bouillon (broth) as vitamin A palmitate (VAP). Fortifying bouillon cubes with VA is one potential approach to addressing VA deficiency, which is a major public health issue in many low- and lower-income countries. The main question this study aims to answer is to compare the amount of VA that is absorbed by the body from three different VAP formulations... Read More
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
08/12/2025
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Healthy Volunteers, Vitamin A
Register for Updates
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
NCT05912647
Recruiting
The purpose of the study is to learn about the best way to enhance pharmacy-related care for diabetes self-management. This research is being done because we want to improve use of medicines and diabetes management among adults with type 2 diabetes and find out which of type of support may improve diabetes self-management for adults. Participants will be assigned to one of 4 groups, and will either: * receive care as usual; or, * receive added medicine management support from a pharmacist; or... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/12/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Diabetes, Diabetes Type 2
Register for Updates
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
NCT05685602
Recruiting
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/12/2025
Locations: University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin +1 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
NCT06285643
Recruiting
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
08/12/2025
Locations: University of Wisconsin (Neurology), Madison, Wisconsin
Conditions: Parkinson Disease
Register for Updates